About Ruby CY Lin
I help organisations build academic-industry hybrid teams. I have skill sets that are interchangeable between academia and industry. I have a proven track record of managing large scale multi-discipline projects within budget and time constraints. I am an effective communicator and collaborator, and have experience in mentoring, management and leadership. This is reflected in my capacity as a researcher where I was successful in securing over A$5.4 million research funding over the course of the last decade or so, and as the president of Australasian Genomic Technologies Association, a premier professional society in Australasia (2013-5).
I am interested in implementing genomic (personalised) medicine into healthcare and better consumer health policy. My publications are available in ORCID (0000-0003-4163-511X), Google Scholar and Research Gate (>4000 citations), and I have >90 Internationally/nationally peer-reviewed conference presentations.
My key skills are in the discipline of: Genomics, Transcriptomics, Cardiovascular Disease, Obesity, Cancer Biology, Animal models, Nucleic Acid technologies, microRNA, microRNA therapeutics, Systems Biology, Pharmacogenomics, Experimental Design, Budget project grants (strategic and translational perspective), Risk and feasibility assessment, Team Management, Mentoring, Establish networks amongst industry and academia (key stakeholders engagement) and of late ethics and governance for phage therapy clinical trials.
I advocate for women in STEMM and do pro bono career coaching. I volunteer as a primary ethics coordinator and as a parent in the management committee for Out Of School Hours childcare at my kids' school, and I am a mentor for the Junior Science Academy holiday program at Macquarie University. During COVID lockdown I knitted beanies for friends and their babies and for colleagues. We also got a puppy since we are working from home. During the last 7 months I spent a lot of time on Zoom and eating chocolate (sometimes concurrently), as well as spending time writing grants and papers, and mentored/ing young scientists and clinicians who have reached out through LinkedIn.
Subject
Antimicrobials and resistance
Bacteria
Biodiversity
Biofilms
Clinical microbiology
Computational biology
Epidemiology
Microbial genetics
Host defence
Infectious diseases
Microbiomes
Molecular biology
Omics
Physiology
Public health
Systems biology
Viruses
Popular Content
We have published and advocated phage therapy [1-7]. Here we describe our effort to build a national consortium aimed at delivering phage therapeutics, in an Australian context.
In an ideal world, a phage biobank would be a facility that serves as a primary research and therapeutic development resource for researchers studying critical infection, as well as to the wider community of infectious diseases, industry and biotech with an interest in critical infection.